Impact of treatment and clinical characteristics on the survival of children with medulloblastoma in Mexico.
Front Oncol
; 14: 1376574, 2024.
Article
em En
| MEDLINE
| ID: mdl-38756654
ABSTRACT
Introduction:
Data on medulloblastoma outcomes and experiences in low- and middle-income countries, especially in Latin America, is limited. This study examines challenges in Mexico's healthcare system, focusing on assessing outcomes for children with medulloblastoma in a tertiary care setting.Methods:
A retrospective analysis was conducted, involving 284 patients treated at 21 pediatric oncology centers in Mexico.Results:
High-risk patients exhibited markedly lower event-free survival than standard-risk patients (43.5% vs. 78.3%, p<0.001). Influential factors on survival included anaplastic subtype (HR 2.4, p=0.003), metastatic disease (HR 1.9, p=0.001); residual tumor >1.5cm², and lower radiotherapy doses significantly impacted event-free survival (EFS) and overall survival (OS). Platinum-based chemotherapy showed better results compared to the ICE protocol in terms of OS and EFS, which was associated with higher toxicity. Patients under 3 years old displayed notably lower OS and EFS compared to older children (36.1% vs. 55.9%, p=0.01).
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
País/Região como assunto:
Mexico
Idioma:
En
Revista:
Front Oncol
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
México